摘要
目的:观察蒽环类药物治疗对BRCA1/2基因突变的乳腺癌(breast cancer,BC)患者心功能的影响。方法:研究对象为288例乳腺癌患者,长期接受蒽环类药物治疗,且血压正常。据基因不同,分为BRCA1/2基因突变患者组(BRCA1/2组,n=138)和散发患者组(散发组,n=150)。通过超声心动图监测并比较二组患者的左室射血分数(LVEF)和整体纵向应变(GLS)。结果:BRCA1/2基因突变患者蒽环类药物治疗时间显著长于散发组患者[(93. 6±15. 6)个月vs (49. 2±10. 8)个月,P <0. 001]。两组间血流动力学和超声心动图变量差异无统计学意义(均P> 0. 05),绝大多数患者LVEF(92. 4%)与GLS(83. 3%)指标正常,两组患者LVEF与GLS异常患者比例差异无统计学意义(P> 0. 05)。结论:标准剂量的辅助蒽环类药物治疗对BRCA1/2基因突变BC患者心脏功能无显著影响。
Objective: To evaluate the effect of cardiac function in breast cancer( BC) patients with BRCA1/2 mutation treated with anthracyclines. Methods: The subjects were 288 BC patients with normal blood pressure receiving long-term treatment of anthracycline. According to different genes,the patients were divided into BRCA1/2 gene mutation patients group( BRCA1/2 group,n = 138) and sporadic patients group( sporadic group,n = 150). Monitored and compared left ventricular ejection fraction( LVEF) and the overall longitudinal strain( GLS) of the two groups of patients by echocardiography. Results: The BRCA1/2 group had longer anthracycline treatment-to-enrollment time[( 93. 6 ± 15. 6) months vs( 49. 2 ± 10. 8) months,P < 0. 001]. There were no significant differences in heart function and hemodynamic variables between two groups( all P > 0. 05). Most of the patients had normal LVEF( 92. 4%)and GLS( 83. 3 %). The differences of two groups with abnormal LVEF and GLS differences( P > 0. 0 5).Conclusion: The cardiac risk with the use of standard-doses of adjuvant anthracyclines in treatment of BRCA1/2 mutation carriers with BC.
作者
熊英
马红娥
刘宝堂
朱学进
陈刚
高西绪
Xiong Ying;Ma Honge;Liu Baotang;Zhu Xuejin;Chen Gang;Gao Xixv(Department of Internal Medicine-Cardiovascular,the Peoples Hospital of Lueyang County,Shaanxi Hanzhong724300,China;Department of Respiratory Endocrinology,,the Peoples Hospital of Lueyang County,Shaanxi Hanzhong724300,China;Department of Gastroenterology,the Peoples Hospital of Lueyang County,Shaanxi Hanzhong724300,China;Department of Neurology,the Peoples Hospital of Lueyang County,Shaanxi Hanzhong724300,China;Department of Traditional Chinese Medicine,the Peoples Hospital of Lueyang County,Shaanxi Hanzhong724300,China)
出处
《现代肿瘤医学》
CAS
2019年第2期252-255,共4页
Journal of Modern Oncology
